Abstract
Introduction. In 70 % of patients with metastases of breast cancer in the ovaries, ovarian damage is detected simultaneously with the primary tumor, which affects the choice of tactics for diagnosis and treatment of such patients. Materials and methods . The data of 30 patients with breast cancer with ovarian metastases and 35 patients with breast cancer without metastatic ovarian damage, which comprised the main and control groups. The groups were comparable in terms of main demographic and clinical features. Results. In the study of distant indicators, it is proved that the presence of metastases in the ovaries is a reliable adverse factor predicting a 3-year overall survival of patients older than 50 years who are in menopause and who received combined treatment. Conclusions. Surgical treatment significantly increases the 3and 5-year overall survival of breast cancer patients with ovarian metastases (83.3 %), while the combined treatment of such patients does not significantly affect overall survival despite the high sensitivity of breast cancer to chemotherapy. This may be due to the fact that the patients included in the study who received the combined treatment had metastases to other organs (liver, lungs, bones).
Highlights
In 70 % of patients with metastases of breast cancer in the ovaries, ovarian damage is detected simultaneously with the primary tumor, which affects the choice of tactics for diagnosis and treatment of such patients
In the study of distant indicators, it is proved that the presence of metastases in the ovaries is a reliable adverse factor predicting a 3-year overall survival of patients older than 50 years who are in menopause and who received combined treatment
Surgical treatment significantly increases the 3- and 5-year overall survival of breast cancer patients with ovarian metastases (83.3 %), while the combined treatment of such patients does not significantly affect overall survival despite the high sensitivity of breast cancer to chemotherapy. This may be due to the fact that the patients included in the study who received the combined treatment had metastases to other organs
Summary
In 70 % of patients with metastases of breast cancer in the ovaries, ovarian damage is detected simultaneously with the primary tumor, which affects the choice of tactics for diagnosis and treatment of such patients. У 21 больной (70,0 %) метастатическое поражение яичников было выявлено одновременно с первичной опухолью, при этом время от прогрессирования (DFI) составило 0, у 3 больных (10,0 %) – до 1 года (DFI менее 12 мес), и у 6 больных (20,0 %) прогрессирование рака молочной железы с метастазированием в яичники наблюдалось через год и более от начала лечения. Все 30 больных (100,0 %) с метастазами рака молочной железы в яичниках получили хирургическое лечение, из них 20 больным (66,7 %) была проведена комбинированная терапия, включающая хирургическое лечение в объеме двусторонней тубовариэктомии (13 больным) или экстирпации матки с придатками (7 больным) и химиотерапию. Что период наибольшего риска для больных основной группы находился между 2-м и 3-м годами от начала лечения, именно в это время наблюдается наибольшее снижение общей выживаемости больных с метастазами рака молочной железы в яичники. Overall survival of patients in the main and control groups
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
